Skip to content
Issues
CURRENT VOLUME
Volume 74, Issue 1
Volume 74, Issue 2
Volume 74, Issue 3
PREVIOUS VOLUME
Volume 73, Issue 6
Volume 73, Issue 5
Volume 73, Issue 4
Volume 73, Issue 3
Volume 73, Issue 2
Volume 73, Issue 1
FULL ARCHIVE
SUBSCRIBE
Forum
CURRENT VOLUME
Volume 74 Forum
PREVIOUS VOLUMES
Volume 73
Volume 72
Volume 71
Volume 70
Volume 69
Volume 68
Volume 67
Symposia
Annual Symposium
Federal Circuit
Submissions
About
Membership
Alumni
Mastheads
Current Masthead
Volume 73 Masthead
Volume 72 Masthead
Volume 71 Masthead
Volume 70 Masthead
Volume 69 Masthead
Volume 68 Masthead
Volume 67 Masthead
Volume 66 Masthead
Volume 65 Masthead
Volume 64 Masthead
Volume 63 Masthead
Volume 62 Masthead
Volume 61 Masthead
Volume 60 Masthead
Publications by Our Staff
AULR Presents: My Favorite Law Review Article
Faculty Advisory Committee
Copyright & Reprints
Issues
CURRENT VOLUME
Volume 74, Issue 1
Volume 74, Issue 2
Volume 74, Issue 3
PREVIOUS VOLUME
Volume 73, Issue 6
Volume 73, Issue 5
Volume 73, Issue 4
Volume 73, Issue 3
Volume 73, Issue 2
Volume 73, Issue 1
FULL ARCHIVE
SUBSCRIBE
Forum
CURRENT VOLUME
Volume 74 Forum
PREVIOUS VOLUMES
Volume 73
Volume 72
Volume 71
Volume 70
Volume 69
Volume 68
Volume 67
Symposia
Annual Symposium
Federal Circuit
Submissions
About
Membership
Alumni
Mastheads
Current Masthead
Volume 73 Masthead
Volume 72 Masthead
Volume 71 Masthead
Volume 70 Masthead
Volume 69 Masthead
Volume 68 Masthead
Volume 67 Masthead
Volume 66 Masthead
Volume 65 Masthead
Volume 64 Masthead
Volume 63 Masthead
Volume 62 Masthead
Volume 61 Masthead
Volume 60 Masthead
Publications by Our Staff
AULR Presents: My Favorite Law Review Article
Faculty Advisory Committee
Copyright & Reprints
Search
Close
COMMENT: The Rx-to-OTC Switch of Claritin, Allegra, and Zyrtec: An Unprecedented FDA Response to Petitioners and the Protection of Public Health
Author: Holly M. Spencer
By Holly M. Spencer
Share this post
Facebook
Twitter
Contact Us
